Dacarbazine

interleukin 2 ; Homo sapiens







12 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 24674910 Immunotherapy in Melanoma: Recent Advances and Promising New Therapies. 2015 Apr 1
2 26310907 Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma. 2015 Dec 3
3 24893857 Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. 2014 Sep 2
4 15779861 Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma. 2005 1
5 14669796 IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC. 2003 1
6 12073777 A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha. 2002 Mar-Apr 1
7 12132295 [Experiences with therapy of stage IV metastatic malignant melanoma with "Legha Protocol" polychemoimmunotherapy]. 2002 Jun 1
8 8695281 Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma. 1996 Apr 2
9 7496166 Addition of dacarbazine or cisplatin to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effects. 1995 Aug 2
10 7666481 Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2. 1995 Jun 21 2
11 1409265 Antagonistic effect of IL-2 on DTIC-induced impairment of tumor-specific cell-mediated immunity in vitro. 1992 Sep 1
12 2249333 Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. 1990 1